Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus

NCT01211470 is registered in ClinicalTrials.gov with PolyMedix, Inc. as lead sponsor.

NCT NCT01211470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01211470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus Aureus
Lead sponsor
PolyMedix, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
March 31, 2012
Enrollment
215 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

(susceptible or methicillin resistant), acute bacterial skin and skin-structure infection(absssi) due to staphylococcus aureus (mssa)